SoloHealth survey finds widespread lack of awareness about health insurance marketplaces
SANTA CLARA, Calif. — Most consumers have "no" or "a little bit" of knowledge about the health insurance marketplaces set to open on Tuesday, according to a new survey.
Kiosk maker SoloHealth announced the results of the survey at the Health 2.0 conference in Santa Clara, Calif., showing little or no awareness among 64% of respondents. Fifty-six percent didn’t know before taking the survey that the government may pay for a portion of insurance for those who qualify, and 60% of those surveyed who have insurance don’t know how the law will affect them, along with 53% of those without insurance. The survey was conducted among 13,600 people through SoloHealth Station kiosks at 3,200 retail locations around the country from Sept. 12-22.
The company recently formed a partnership with the Department of Health and Human Services to help promote awareness and information around the new insurance marketplaces and Healthcare.gov. It also has partnerships with insurance providers to link potential buyers with plans to help consumers make appropriate decisions for their insurance needs.
FDA approves UCB’s Cimzia for psoriatic arthritis
BRUSSELS — The Food and Drug Administration has approved a new usage for a drug made by UCB, the drug maker said Monday.
UCB announced the approval of Cimzia (certolizumab pegol) for psoriatic arthritis in adults. Psoriatic arthritis is an inflammatory, autoimmune condition that causes pain, swelling and stiffness around the joints, usually combined with the skin lesions of psoriasis. The drug was already approved to treat rheumatoid arthritis and Crohn’s disease.
"The FDA’s approval of Cimzia for the treatment of active PsA provides an additional, effective treatment option for those living with the condition," director of rheumatology research at the Seattle-based Swedish Medical Center and University of Washington medicine professor Philip Mease said.
Amneal buys four generic drugs from Actavis
BRIDGEWATER, N.J. — Amneal Pharmaceuticals has bought rights to four generic drugs from Actavis, Amneal said Monday.
The generic drug maker announced the purchase of four drugs, two of which are currently marketed, one of which is awaiting Food and Drug Administration approval, and another of which is approved, but not marketed. The respective drugs are the contraceptive Zenchent Fe (norethindrone acetate; ethinyl estradion), a generic version of Femcon Fe; another generic norethindrone acetate and ethinyl estradiol product that is a generic version of Lo Loestrin Fe; the osteoporosis drug risendronate sodium, a generic version of Atelvia; and a third norethindrone acetate and ethinyl estradiol product that is a generic version of Loestrin 24 Fe.
Amneal’s acquisition of the drugs is dependent on the closing of Actavis’ purchase of Warner Chilcott. Financial terms of the Amneal-Actavis deal were not disclosed.